Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis

CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062

Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research